Table 2.

Baseline clinical, laboratory and medication-related characteristics of the HIV-infected children on ART at Debre-Markos Referral Hospital, Northwest Ethiopia, from January 1, 2005 to March 31, 2019 (N = 408)

Characteristics	Categories	Frequency (N)	Percentage (%)
History of PMTCT	Yes	56	13.7
	No	229	56.1
	Not recorded	123	30.2
History of OIs	Yes	215	52.7
	No	193	47.3
Weight for age	Normal	207	50.7
	Underweight	201	49.3
Weight for height	Normal	311	76.2
	Wasted	97	23.8
Height for age	Normal	197	48.3
	Stunted	211	51.7
WHO clinical stage	Stage I and II	212	52.0
	Stage III and IV	196	48.0
CD4 counts or %	Above the threshold	277	67.9
	Below the thresheold	131	32.1
Hgb level	≥ 10 g/dl	366	89.7
	<  10 g/dl	42	10.3
ART eligibility criteria	Test and treat	67	16.4
	CD4 or WHO staging	341	83.6
Type of regimen at baseline	Nevirapine base	272	66.7
	Efaveraze base	86	21.1
	Protease inhibitor base	50	12.3
Ever taking IPT	Yes	217	53.2
	No	191	46.8
ART adherence	Good	321	78.7
	Fair/ poor	87	21.3
Past OI prophylaxis	Yes	248	60.8
	No	160	39.2
ART side effect	Yes	19	4.7
	No	389	95.3
Regimen change	Yes	84	20.6
	No	324	79.4
Treatment failure	Yes	20	4.9
	No	388	95.1
Functional status	Working	153	53.3
	Ambulatory	113	39.4
	Bed ridden	21	7.3
Developmental status	Appropriate	73	60.3
	Delayed	41	33.9
	Regressed	7	5.8

PMTCT Prevention of Mother To Child Transmission, OIs Opportunistic Infections, WHO World Health Organization, Hgb Hemoglobin, CD4 Cluster of differentiation 4, and ART Antiretroviral Therapy